Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis Breceiving long-term nucleos(t)ide analogue therapy
We investigated the patterns of serum HBsAg kinetics and their association with therapeutic outcomes in genotype B- or C-infected CHB patients receiving long-term NA therapy.
Chronic Hepatitis B
Serum HBsAg Levels
Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections
CRP showed to be a strong predictor of early hospital readmission and 6-month mortality in patients with cirrhosis after hospitalization for bacterial and/or fungal infection.
Bacterial And/Or Fungal Infection
Hepatitis B virus pregenomic RNA in hepatocellular carcinoma:A nosological and prognosticdeterminant
HCC replicating HBV represents a subtype of weakly invasive HCC with a transcriptomic signature.
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
This study investigated the potential to discontinue tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative patients.
Discontinue TDF Therapy
Fine-Tuning Hepatitis B Treatment Strategies（2）
Gao and colleagues evaluated the effect of antiviral therapy on the incidence of HCC in patients with cirrhosis with lower HBV DNA levels.
HBV DNA Load
Fine-Tuning Hepatitis B Treatment Strategies（1）
Early diagnosis of HBV through effective screening programs allows timely initiation of therapy to prevent disease progression and decompensation.
Chronic Hepatitis B
Systematic review with meta-analysis the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus
The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77% .
Medical Management of Severe Alcoholic Hepatitis
Medical management recommendations for severe alcoholic hepatitis
Best Practice Advice
Severe Alcoholic Hepatitis
China Clears First All-Oral Chronic Hepatitis C Regimen
The China Food and Drug Administration (CFDA) has approved the country's first all-oral, interferon-and ribavirin-free direct-acting antiviral regimen for chronic hepatitis C virus (HCV) infection.
Eiger Files New Drug Application for Lambda as Hepatitis D Therapy, Starts Clinical Trials
Unfortunately HDV remains a large unmet medical need because of the lack of any effective therapy for this most aggressive form of viral hepatitis.
PRC Online Drug Information Service Certificate No.：(M)-Non-operating-2014-0006
Copyright @ Cosunter Co., Ltd. 2006-2016. All rights reserved
M. ICP. B. No. 11026770 Website statistics